Cancers,
Journal Year:
2024,
Volume and Issue:
16(6), P. 1209 - 1209
Published: March 19, 2024
Renal
cell
carcinoma
(RCC)
affects
over
400,000
patients
globally
each
year,
and
30%
of
present
with
metastatic
disease.
Current
standard
care
therapy
for
RCC
involve
TKIs
ICIs,
including
combinatorial
strategies,
but
this
offers
only
modest
clinical
benefit.
Novel
treatment
approaches
are
warranted,
cell-based
immunotherapies
hold
significant
promise.
These
currently
being
tested
in
the
pre-clinical
setting
early
phase
trials.
Here,
we
review
landscape
cellular
immunotherapy
context
available
therapies,
a
particular
focus
on
defining
current
best
antigenic
targets,
range
products
explored
RCC,
how
advanced
engineering
solutions
may
further
enhance
these
therapies
space.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 7, 2025
Gastric
cancer
is
a
common
malignant
tumor
of
the
digestive
tract,
and
its
treatment
remains
significant
challenge.
In
recent
years,
role
various
immune
cells
in
microenvironment
progression
has
gained
increasing
attention.
Immunotherapy,
primarily
based
on
checkpoint
inhibitors,
notably
improved
prognosis
patients
with
gastric
cancer;
however,
challenges
regarding
therapeutic
efficacy
persist.
Histological
features
within
microenvironment,
such
as
tertiary
lymphoid
structures
(TLSs),
tumor-infiltrating
lymphocytes,
proportion
intratumoral
stroma,
are
emerging
potentially
effective
prognostic
factors.
cancer,
TLSs
may
serve
local
hubs,
enhancing
ability
to
interact
recognize
antigens,
which
closely
linked
effectiveness
immunotherapy
survival
rates
patients.
However,
specific
cell
type
driving
TLS
formation
tumors
not
yet
been
elucidated.
Mature
B-cell
regions
containing
germinal
centers.
During
center
formation,
B
undergo
transformations
become
mature
function,
exerting
anti-tumor
effects.
Therefore,
targeting
could
provide
new
avenues
for
immunotherapy.
This
review,
combined
current
research
elaborates
relationship
between
aiming
guidance
precise
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
15
Published: March 7, 2025
Anti-tumor
immunity,
including
innate
and
adaptive
immunity
is
critical
in
inhibiting
tumorigenesis
development
of
tumor.
The
needs
specific
lymph
organs
such
as
tertiary
lymphoid
structures
(TLSs),
which
are
highly
correlated
with
improved
survival
outcomes
many
cancers.
In
recent
years,
increasing
attention
on
the
TLS
tumor
microenvironment,
TLSs
have
emerged
a
novel
target
for
anti-tumor
therapy.
Excitingly,
studies
shown
contribution
to
immune
responses.
However,
it
unclear
how
form
more
effectively
defense
against
through
formation.
Recent
that
inflammation
plays
role
Interestingly,
also
found
gut
microbiota
can
regulate
occurrence
inflammation.
Therefore,
we
here
summarize
potential
effects
microbiota-
mediated
or
immunosuppression
formation
environments.
Meanwhile,
this
review
explores
manipulate
mature
regulating
microbiota/metabolites
associated
signal
pathways
potentially
lead
next-generation
cancer
immunotherapy.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: June 27, 2024
Background
Clear
Cell
Renal
Carcinoma
(ccRCC)
is
the
most
common
type
of
kidney
cancer,
characterized
by
high
heterogeneity
and
complexity.
Recent
studies
have
identified
mitochondrial
defects
autophagy
as
key
players
in
development
ccRCC.
This
study
aims
to
delve
into
changes
mitophagic
activity
within
ccRCC
its
impact
on
tumor
microenvironment,
revealing
role
cell
metabolism,
development,
survival
strategies.
Methods
Comprehensive
analysis
tissues
using
single
sequencing
spatial
transcriptomics
reveal
mitophagy
Mitophagy
was
determined
be
altered
among
renal
clear
cells
gene
set
scoring.
Key
populations
prognostic
genes
were
NMF
approaches.
The
UBB
also
demonstrated
vitro
experiments.
Results
Compared
normal
tissue,
various
types
exhibited
significantly
increased
levels
mitophagy,
especially
cells.
associated
with
levels,
such
UBC,
UBA52,
TOMM7,
UBB,
MAP1LC3B,
CSNK2B,
identified,
their
expression
closely
linked
poor
patient
prognosis.
Particularly,
ubiquitination
process
involving
found
crucial
for
quality
control.
Conclusion
highlights
central
regulatory
factors
ccRCC,
significance
disease
progression.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Aug. 28, 2024
Tertiary
lymphoid
structures
(TLSs)
are
defined
as
aggregates
formed
in
non-hematopoietic
organs
under
pathological
conditions.
Similar
to
secondary
(SLOs),
the
formation
of
TLSs
relies
on
interaction
between
tissue
inducer
(LTi)
cells
and
organizer
(LTo)
cells,
involving
multiple
cytokines.
Heterogeneity
is
a
distinguishing
feature
TLSs,
which
may
lead
differences
their
functions.
Growing
evidence
suggests
that
associated
with
various
diseases,
such
cancers,
autoimmune
transplant
rejection,
chronic
inflammation,
infection,
even
ageing.
However,
detailed
mechanisms
behind
these
clinical
associations
not
yet
fully
understood.
The
by
TLS
maturation
localization
affect
immune
function
also
unclear.
Therefore,
it
necessary
enhance
understanding
development
at
cellular
molecular
level,
allow
us
utilize
them
improve
microenvironment.
In
this
review,
we
delve
into
composition,
mechanism,
potential
therapeutic
applications
TLSs.
Furthermore,
discuss
implications
role
markers
response
prognosis.
Finally,
summarize
methods
for
detecting
targeting
Overall,
provide
comprehensive
aim
develop
more
effective
strategies.
BMC Cancer,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: Jan. 15, 2025
There
is
still
no
consensus
regarding
the
correlation
between
TLS
and
prognosis
of
lung
cancer
patients.
This
meta-analysis
aimed
to
investigate
association
in
patients
with
cancer.
In
addition,
prognostic
value
for
efficacy
immunotherapy
was
also
studied.
We
systematically
searched
PubMed,
Embase,
Cochrane
Library,
Web
Science
databases
from
database
inception
November
1,
2023.
The
hazard
ratio
(HR)
corresponding
95%
confidence
interval
(CI)
overall
survival
(OS),
disease-free
(DFS),
recurrence-free
(RFS),
progression-free
(PFS)
disease-specific
(DSS)
were
extracted
merged
STATA
14.0.
study
protocol
registered
PROSPERO
(CRD42024502483).
A
total
17
studies
comprising
4291
included
this
meta-analysis.
pooled
results
revealed
that
high
TLS/TLS
+
had
better
OS
(HR
=
0.66,
CI:
0.50–0.88),
DFS
0.46,
0.33–0.64),
DSS
0.48,
0.39–0.60)
RFS
0.43,
0.33–0.57).
High
tended
have
longer
PFS
than
low
0.68,
0.35–1.35).
Interestingly,
Asia
subgroup,
especially
significant,
whereas
there
significant
difference
Europe.
who
received
neoadjuvant
chemoimmunotherapy,
associated
prolonged
0.21,
95%CI:
0.05–0.93).
improved
an
response
chemoimmunotherapy
patients,
suggesting
may
be
a
biomarker
promising
predictive
marker
chemoimmunotherapy.
However,
additional
original
are
needed
further
confirm
these
findings.
Journal of Clinical Investigation,
Journal Year:
2025,
Volume and Issue:
135(7)
Published: March 31, 2025
Tertiary
lymphoid
structures
(TLS)
in
the
tumor
microenvironment
(TME)
are
emerging
solid-tumor
indicators
of
prognosis
and
response
to
immunotherapy.
Considering
that
tumorigenesis
requires
metabolic
reprogramming
subsequent
TME
remodeling,
discovery
TLS
regulators
is
expected
produce
immunotherapeutic
targets.
To
identify
such
regulators,
we
constructed
a
metabolism-focused
sgRNA
library
performed
an
vivo
CRISPR
screening
orthotopic
lung
mouse
model.
Combined
with
The
Cancer
Genome
Atlas
database
analysis
TLS-related
hub
genes,
found
loss
Acat1
cells
sensitized
tumors
anti-PD1
treatment,
accompanied
by
increased
TME.
Mechanistic
studies
revealed
ACAT1
resulted
mitochondrial
protein
hypersuccinylation
subsequently
enhanced
oxidative
metabolism,
which
impeded
formation.
Elimination
ROS
NAC
or
knockdown
promoted
B
cell
aggregation
construction.
Consistently,
data
from
tissue
microassays
305
patients
cancer
showed
were
more
abundant
non-small
(NSCLC)
tissues
lower
expression.
Intratumoral
expression
was
associated
poor
immunotherapy
outcomes
NSCLC.
In
conclusion,
our
results
identified
as
regulator
promising
target
Journal for ImmunoTherapy of Cancer,
Journal Year:
2024,
Volume and Issue:
12(7), P. e009232 - e009232
Published: July 1, 2024
Background
Patients
with
breast
cancer
brain
metastases
(BCBM)
experience
a
rapid
decline
in
their
quality
of
life.
Recently,
tertiary
lymphoid
structures
(TLSs),
analogs
secondary
organs,
have
attracted
extensive
attention.
However,
the
potential
clinical
implications
TLSs
BCBMs
are
poorly
understood.
In
this
study,
we
evaluated
density
and
composition
described
prognostic
value.
Methods
Clinicopathological
data
were
collected
from
98
patients
(2015–2021).
evaluated,
TLS
scoring
system
was
constructed.
Differences
progression-free
survival
(PFS)
overall
(OS)
between
groups
calculated
using
Kaplan-Meier
method.
Immunohistochemistry
multiplex
immunofluorescence
(mIF)
used
to
assess
heterogeneity.
Results
identified
47
BCBM.
High
indicated
favorable
(OS,
p=0.003;
PFS,
p<0.001).
positively
associated
OS
(p=0.0172)
PFS
(p=0.0161)
human
epidermal
growth
factor
receptor
type
2-positive
subtype,
prolonged
(p=0.0482)
triple-negative
subtype.
The
mIF
results
showed
significant
differences
percentages
T
follicular
helper
(Tfh)
cells,
M2
macrophages,
cytotoxic
lymphocytes,
CD8
+
TIM-3
lymphocytes
scores
0–3
(cytotoxic
p=0.044;
Tfh,
p=0.021;
p=0.033;
p=0.018).
Furthermore,
novel
nomograms
incorporating
other
clinicopathological
predictors
demonstrated
prominent
predictability
1-year,
3-year,
5-year
outcomes
(area
under
curve
>0.800).
Conclusion
Our
highlight
impact
abundance
on
Additionally,
immune
proposed
predict
prognosis